Prolongation of GLP-1 Adherence When Using Continuous Glucose Monitoring

Recruiting Observational Study
Diabetes Mellitus
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
800 (estimated)
Sponsor
Abbott Diabetes Care · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This study is to see if the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) will help prolong the length of time people with diabetes maintain adherence to glucagon-like peptide 1 (GLP-1/GIP) agonists.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Subject must be at least 18 years of age. 2. Subject must be able to read and understand English. 3. Subject must have a type 2 diabetes diagnosis. 4. In the investigator's opinion, subject must meet the criteria for beginning use of GLP-1 or GIP/GLP-1 medications for managem…
Contacts

Mohamed Mohamed Nada, PhD

5107495416

adc.clinical@abbott.com

CONTACT

Shridhara Karinka, PhD

510 7495416

adc.clinical@abbtott.com

CONTACT